Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J. et al.
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): A descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

Lancet Oncol 2017;
18: 732-42

Bibliographische Angaben herunterladen

Aufrufen in: